Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: New evidence

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 921-930

  Tonini, Giuseppe ^a   Fratto, Maria Elisabetta ^a   Imperatori, Marco ^a   Pantano, Francesco ^a   Vincenzi, Bruno ^a   Santini, Daniele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

bevacizumab; predictive factors; renal cell carcinoma; sorafenib; sunitinib; temsirolimus

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; FAS LIGAND; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERLEUKIN 2; INTERLEUKIN 8; LACTATE DEHYDROGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHORYLATED S6 KINASE; PLACENTAL GROWTH FACTOR; PROTEIN BCL 2; S6 KINASE; SOLUBLE VASCULOTROPIN RECEPTOR 2; SOLUBLE VASCULOTROPIN RECEPTOR 3; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; BODY MASS; BONE METASTASIS; CANCER SURVIVAL; DENDRITIC CELL; DIASTOLIC HYPERTENSION; DRUG EFFICACY; DRUG RESPONSE; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS; ENDOTHELIUM CELL; GENE MUTATION; HAND FOOT SYNDROME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTHYROIDISM; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; NEPHRECTOMY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SYSTOLIC HYPERTENSION; T LYMPHOCYTE; THROMBOCYTOSIS; TUMOR ESCAPE; TUMOR VOLUME;

ADULT; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; RISK; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 79959805941     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.63     Document Type: Review

References (94)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J. Clin. 59(4), 225-249 (2009
2. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20(23), 4559-4566 (2002 (Pubitemid 35402959)
3. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23(4), 832-841 (2005 (Pubitemid 46224183)
4. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(9), 2859-2867 (1999
5. Bhargava P. VEGF kinase inhibitors: how do they cause hypertension? Am. J. Physiol. Regul. Integr. Comp. Physiol. 297(1), R1-R5 (2009
6. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol. 24(9), 1363-1369 (2006
7. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann. Oncol. 19, 927-934 (2008 (Pubitemid 351627309)
8. Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J. Clin. Oncol. 24, 1363-1369 (2006 (Pubitemid 46621999)
9. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. Heart. Circ. Physiol. 274, H1054-H1058 (1998
10. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J. Biol. Chem. 274, 25130-25135 (1999
11. Li B, Ogasawara AK, Yang R et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 39, 1095-1100 (2002 (Pubitemid 34620130)
12. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49, 186-193 (2007 (Pubitemid 46178407)
13. Maitland ML, Moshier K, Imperial J et al. Blood pressure as a biomarker for sorafenib, an inhibitor of VEGF signalling pathway. J. Clin. Oncol. 24(Suppl. 87), (2006) (Abstract 2035
14. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann. Oncol. 20(2), 227-230 (2009
15. Rini BI, Cohen DP, Lu D et al. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. Presented at: American Society of Clinical Oncology GU. San Francisco, CA, USA, 5-7 March 2010.
16. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann. Oncol. 20(5), 966-967 (2009
17. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon a versus interferon a monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010
18. Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med. 358(1), 95-97 (2008
19. Li WW. Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging. Acad. Radiol. 7, 800-811 (2000
20. Krajewski KM, Guo M, Van den Abbeele AD et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur. Urol. 59(5), 856-862 (2011
21. Thiam R, Fournier LS, Trinquart L et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann. Oncol. 21(5), 936-941 (2010
22. Smith AD, Shah SN, Rini BI et al. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. Am. J. Roentgenol. 194(6), 1470-1478 (2010
23. Lassau N, Koscielny S, Albiges L et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin. Cancer Res. 16(4), 1216-1225 (2010
24. Beuselinck B, Rixe O, Oudard S et al. Site of metastasis in metastatic clear cell renal cell carcinoma (mccRCC) and outcome of treatment with sunitinib. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010.
25. Beuselinck B, Oudard S, Rixe O et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann. Oncol. 22(4), 794-800 (2011
26. Basappa NS, Elson P, Golshayan AR et al. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer 117(6), 1183-1189 (2011
27. Luca A, Angermayr B, Bertolini G et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 13, 1174-1180 (2007 (Pubitemid 47307228)
28. Kim WR, Biggins SW, Kremers WK et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N. Engl. J. Med. 359, 1018-1026 (2008
29. Huo TI, Lin HC, Hsia CY et al. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig. Liver. Dis. 40, 882-889 (2008
30. Kim HS, Yi SY, Jun HJ et al. Clinical outcome of gastric cancer patients with bone marrow metastases. Oncology 73(3-4), 192-197 (2007 (Pubitemid 351630049)
31. Gandhi L, Johnson BE. Paraneoplastic syndromes associated with small cell lung cancer. J. Natl Compr. Canc. Netw. 4(6), 631-638 (2006 (Pubitemid 44265469)
32. Vasudev NS, Brown JE, Brown SR et al. Prognostic factors in renal cell carcinoma association of preoperative sodium concentration with survival. Clin. Cancer Res. 14(6), 1775-1781 (2008 (Pubitemid 351469463)
33. Jeppesen AN, Jensen HK, Donskov F et al. Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma. Br. J. Cancer 102(5), 867-872 (2010
34. Choueiri TK, Xie W, Kollmannsberger CK et al. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelialgrowth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration. J. Clin. Oncol. 28 (Suppl. 15) (2010) (Abstract 4524
35. Hutson TE, Davis ID, Machiels JP et al. Predictive and prognostic factors in Phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Presented at: European Society for Medical Oncology Congress. Stockholm, Sweden, 12-16 September 2008.
36. Michaelson MD, Cohen MP, Li S et al. Hand-foot syndrome (HFS) as a potential biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SUJ. Clin. Oncol. 29(Suppl. 7) (2011) (Abstract 320
37. Schmidinger M, Zielinski CC. Defining risk status in the first-line treatment of metastatic renal cell carcinoma. J. Cancer Res. Clin. Oncol. 136(7), 961-968 (2010
38. Schmidinger M, Vogl UM, Bojic M et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117(3), 534-544 (2011
39. Medioni J, Arakelian N, Fournier L et al. Relation between lactate dehydrogenase (LDH) during two first cycles in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SUPresented at: ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
40. Armstrong AJ, George DJ, Halabi S Evaluation of serum lactate dehydrogenase (LDH) as a predictive biomarker for mTOR inhibition in patients with metastatic renal cell carcinoma (RCCPresented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010.
41. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc. Natl Acad. Sci. USA. 104(43), 17069-17074 (2007 (Pubitemid 350210993)
42. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two Phase I trials. Ann. Oncol. 16(4), 558-565 (2005 (Pubitemid 40613321)
43. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006 (Pubitemid 46630489)
44. Norden-Zfoni A, Desai J, Manola J et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 13(9), 2643-2650 (2007 (Pubitemid 46788031)
45. Deprimo SE, Bello CL, Smeraglia J et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 5, 32 (2007
46. Rini BI, Michaelson MD, Rosenberg JE et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 26(22), 3743-3748 (2008
47. Peña C, Lathia C, Shan M et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin. Cancer Res. 16(19), 4853-4863 (2010
48. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4(12), 941-952 (2004 (Pubitemid 39620069)
49. Rissoan MC, SoumelisV, Kadowaki N et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283, 1183-1186 (1999
50. Della BS, Gennaro M, Vaccari M et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89(8), 1463-1472 (2003 (Pubitemid 37386601)
51. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3, 483-490 (1997 (Pubitemid 27158075)
52. Gabrilovich D, IshidaT, OyamaT et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11), 4150-4166 (1998 (Pubitemid 28544331)
53. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J. Immunol. 163(6), 3260-3268 (1999 (Pubitemid 29431827)
54. Almand B, Resser JR, Lindman B et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000 (Pubitemid 30305068)
55. Boissel N, Rousselot P, Raffoux E et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 18, 1656-1661 (2004 (Pubitemid 39386344)
56. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer 78, 1573-1577 (1998 (Pubitemid 28550041)
57. Fricke I, Mirza N, Dupont J et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840-4848 (2007 (Pubitemid 47298146)
58. OsadaT, Chong G, Tansik R et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 57, 1115-1124 (2008
59. +DR-dendritic cell precursors. J. Immunol. 166, 848-854 (2001 (Pubitemid 32060237)
60. Schips L, Dalpiaz O, Lipsky K et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur. Urol. 51(1), 168-173 (2007
61. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 72(3), 424-430 (1997 (Pubitemid 27325869)
62. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinomatreatedwith vascular endothelial growth factor-targeted therapy. Cancer 110(3), 543-50 (2007 (Pubitemid 47106142)
63. + dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14(18), 5884-5892 (2008
64. Adotevi O, Pere H, Ravel P et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J. Immunother. 33(9), 991-998 (2010
65. Bui MHT, Seligson D, Han K-R et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9, 802-811 (2003 (Pubitemid 36182618)
66. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11, 3714-3721 (2005 (Pubitemid 40685588)
67. Dudek AZ, Yee RT, Manivel JC, Isaksson R, Yee HO. Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinoma. Anticancer Res. 30(3), 987-992 (2010
68. Choueiri TK, Regan MM, Rosenberg JE et al. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 106(6), 772-778 (2010
69. Atkins M, McDermott D, Regan M et al. Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. ASCO Annual Meeting Proceedings (Post-Meeting EditionJ. Clin. Oncol. 22(14 Suppl.), 4512 (2004
70. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol. Chem. 268, 10425-10432 (1993) (Pubitemid 23150227)
71. Stoesz SP, Gould MN. Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas. Oncogene 11, 2233-2241 (1995 (Pubitemid 26008399)
72. Friedl A, Stoesz SP, Buckley P, Gould MN Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem. J. 31, 433-441 (1999 (Pubitemid 29369301)
73. Matthaeus T, Schulze-Lohoff E, Ichimura T. Co-regulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic rat kidney. J. Am. Soc. Nephrol. 14, 2534-2543 (2001
74. Ohlsson S, Wieslander J, Segelmark M Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies- associated systemic vasculitis in remission. Clin. Exp. Immunol. 131, 528-535 (2003 (Pubitemid 36324145)
75. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am. J. Nephrol. 24, 307-315 (2004 (Pubitemid 39070114)
76. Porta C, Paglino C, De Amici M et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 77(9), 809-815 (2010
77. Ergün S, Hohn HP, Kilic N, Singer BB, Tilki D. Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem. Cell. Rev. 4, 169-177 (2008
78. Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11, 261-262 (2005 (Pubitemid 40460552)
79. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8, 79-88 (2006
80. Escudier BJM, Taylor S, Koscielny C et al. Farace Circulating endothelial cells and progenitor cells in metastatic renal cell carcinoma: predictive value during antiangiogenic therapy? Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 14-16 February 2008.
81. Tomita Y, Kawasaki T, Bilim V, Takeda M, Takahashi K. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells. Int. J. Cancer 68, 132-135 (1996 (Pubitemid 26354591)
82. Nonomura N, Miki T, Yokoyama M et al. A Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem. Biophys. Res. Commun. 229, 945-951 (1996 (Pubitemid 27035821)
83. Kelly JD, Dai J, Eschwege P et al. Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas. Br. J. Cancer 91, 164-170 (2004 (Pubitemid 39013061)
84. Maruyama R, Yamana K, Itoi T et al. Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br. J. Cancer 95(9), 1244-1249 (2006 (Pubitemid 44658490)
85. Rowinsky EK. Targeting the molecular target of rapamycin (mTORCurr. Opin. Oncol. 16, 564-575 (2004 (Pubitemid 39482975)
86. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin. Cell. Dev. Biol. 15, 171-176 (2004 (Pubitemid 38251645)
87. Dufner A, Andjelkovic M, Burgering BM et al. Protein kinase B localization and activation differentially affect S6 kinase 1 activity and eukaryotic translation initiation factor 4E-binding protein 1 phosphorylation. Mol. Cell. Bio. 19, 4525-4534 (1999 (Pubitemid 29242025)
88. Ferrari S, Bandi HR, Hofsteenge J et al. Mitogenactivated 70K S6 kinase. Identification of in vitro 40S ribosomal S6 phosphorylation sites. J. Biol. Chem. 266, 22770-22775 (1991
89. Cho D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 5(6), 379-385 (2007 (Pubitemid 47584475)
90. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 1, 109(11), 2257-2267 (2007 (Pubitemid 46801555)
91. Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70(3), 1063-1071 (2010
92. Figlin RA, de Souza P, McDermott D et al. Analysis of PTEN and HIF-1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-a. Cancer 115(16), 3651-3660 (2009
93. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat. Rev. Clin. Oncol. 7(5), 277-288 (2010
94. Bensalah K, Leray E, Fergelot P et al. Prognostic value of thrombocytosis in renal cell carcinoma. J. Urol. 175(3 Pt 1), 859-863 (2006). (Pubitemid 43199997)